Pharmaceutical - Antibiotics and Infectious diseases, Asia-Pacific


Popular Filters

Leading Chinese hepatitis B vaccine makers stop production; Pfizer drug import halted


China’s Food and Drug Administration announced on January 2 that the country’s three leading manufacturers…

Anti-viralsAntibiotics and Infectious diseasesAsia-PacificBioKangtaiChinaFluconazolePfizerPharmaceuticalRegulationVaccines

MRCF invests in Australian antibiotics start-up Auspherix


Auspherix Pty, an early stage anti-infectives company developing novel antibiotics to treat resistant…

Antibiotics and Infectious diseasesAsia-PacificAuspherixAustraliaFinancialPharmaceuticalResearch

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

Eisai takes over marketing authorization for Gliadel, and joins TB partnership


Japanese drug major Eisai (TYO: 4523) will become the Marketing Authorization Holder for the antineoplastic…

Antibiotics and Infectious diseasesAsia-PacificEisaiGliadelLicensingNobelpharmaOncologyPharmaceutical

UK’s Helperby in deal with Cadila on ARB research and commercialization


Privately-held Indian drugmaker Cadila Pharmaceuticals and UK based antibiotics discovery company, Helperby…

Antibiotics and Infectious diseasesAsia-PacificCadila PharmaceuticalsHelperby TherapeuticsMarkets & MarketingPharmaceuticalResearch

Venus gets GMP certifications from Ukraine


Indian R&D-based drugmaker Venus Remedies (BSE: 526953) has been able to gain a Good Manufacturing Practice…

Antibiotics and Infectious diseasesAsia-PacificEuropeMarkets & MarketingOncologyPharmaceuticalProductionRegulationVenus Remedies

India must address worrying stock out of tuberculosis drugs, says MSF


The Indian government must urgently address the persistent issues and almost routine delays of procuring…

Antibiotics and Infectious diseasesAsia-PacificHealthcareMarkets & MarketingPharmaceuticalPolitics

Cempra out-licenses solithromycin to Toyama Chemical in Japan


USA-based clinical-stage antibiotics developer Cempra (Nasdaq: CEMP) has signed an exclusive license…

Antibiotics and Infectious diseasesAsia-PacificCempraLicensingPharmaceuticalsolithromycinToyama

BioAlliance Pharma pursues development plan for Loramyc in Japan through partner Sosei


French orphan oncology and supportive care specialist BioAlliance Pharma (Euronext Paris: BIO) says its…

Antibiotics and Infectious diseasesAsia-PacificBioAlliance PharmaLoramycOravigPharmaceuticalRegulationResearchSosei

MicuRx joins forces with VC for next-generation antibiotic for China


MicuRx Pharmaceuticals, a privately-held US biopharmaceutical company developing next-generation antibiotics,…

Antibiotics and Infectious diseasesAsia-PacificMergers & AcquisitionsMicuRx PharmaceuticalsMRX-IPharmaceuticalResearchShanghai MengKe Pharma

Pharmaceutical majors unite in Japan to combat H. pylori


On August 31, nine pharmaceutical companies operating in Japan (Kyowa Hakko Kirin, Takeda Pharmaceutical,…

Antibiotics and Infectious diseasesAsia-PacificAstraZenecaGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Regulatory briefs: Amitiza in Japan; Dificid in Canada; Eurartesim roll-out


Sucampo Pharmaceuticals (Nasdaq: SCMP) and Abbott Labs (NYSE: ABT) have received approval from the Ministry…

Abbott LaboratoriesAmitizaAntibiotics and Infectious diseasesAsia-PacificDificidEurartesimGastro-intestinalsMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulationSigma-TauSucampoTropical diseases

TaiGen Biotech out-licenses China rights for nemonoxacin, to Zhejiang Medicine


Taiwan-based TaiGen Biotechnology and China's Zhejiang Medicine Company (SHA: 600216) have signed an…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyZhejiang Medicine

Optimer Pharma could earn $90 million from new Astellas deal


US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

Additional indications in Japan for Diagnogreen and Sawacillin


Japanese drug major Daiichi Sankyo (TYO: 4568) says it has received approval in Japan for a supplemental…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDaiichi SankyoPharmaceuticalRegulationSawacillin

Back to top